medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Methods US Adults Used to Stop Smoking, 2021–2022

Floe Foxon[1], BSc (Hons); Ray Niaura[2], PhD

[1]Department of Data Management and Statistical Analysis, Pinney Associates, Pittsburgh, Pennsylvania

[2]Department of Epidemiology, School of Global Public Health, New York University, New York, New York

Corresponding Author: Floe Foxon (ffoxon@pinneyassociates.com)

Abstract

Nationally representative Centers for Disease Control and Prevention (CDC) survey data were used to identify which subpopulations of US adults had stopped smoking cigarettes for 6 months or longer in the last year and the methods they used. From 2021 through 2022, 2.9 million adults stopped smoking. Most of these were male, non-Hispanic White, aged less than 55 years, college educated, and identified as straight. The most popular method used was nicotine products (53.9%; 1.5 million adults), especially e-cigarettes in combination with other methods (40.8%; 1.2 million) and e-cigarettes alone (26.0%; 0.7 million). The data suggest that interventions to reduce smoking could focus on subpopulations that stopped smoking the least and encourage use of evidence-based methods.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Introduction

Although considerable progress has been made in the last decade in the US to reduce prevalence of combustible cigarette smoking [1], smoking continues as one of the leading causes of chronic disease [2]. Thus, further reductions in smoking prevalence are crucial to preventing or reducing the effects of chronic disease in the US. A previous study identified giving up cigarettes all at once, gradually cutting back on cigarettes, and substituting some cigarettes with e-cigarettes as the most commonly reported stop-smoking methods during quit attempts from 2014 through 2016 [3]. More recent data are needed to understand who stopped smoking since 2016 and how they did it. The objectives of this study were to identify which subpopulations stopped smoking completely (reported having stopped smoking for ≥6 months in the past year as defined in previous research [4]) or tried to stop smoking, and to quantify the methods they used by using the most recent CDC National Health Interview Survey (NHIS) data [5].

Methods

Data on methods used to stop smoking were sourced from CDC's latest NHIS. These data are nationally representative and have low bias [5]. The 2022 NHIS (fielded January–December 2022) asked respondents who had stopped smoking in the past 2 years which methods they used to stop smoking completely. These analyses focused on those respondents who had stopped smoking in the last year (2021 through 2022) and who had stopped smoking for 6 months or longer at the time of the survey. The survey also asked respondents who were still smoking but had tried to stop in the past year which methods they used when they tried. Full details of questionnaire wording are available in online supplemental materials (https://doi.org/10.17605/osf.io/HGMN6). The prevalence of each stop-smoking method was calculated with NHIS sampling weights to provide nationally representative population estimates. NHIS stratum and cluster variables were also used

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

to provide 95% CIs. Demographic characteristics of the sample of adults who stopped smoking or tried to stop (sex, race or ethnicity, age, education, and sexual orientation) were derived from standard NHIS questions, similar to other CDC NHIS publications [6, 7].

Only publicly available, de-identified survey data were used; therefore, this study is exempt from NIH human subjects research under NIH exemption 4 and did not require institutional review board review.

Results

Overall, 2.9 million US adults stopped smoking from 2021 through 2022 and had been stopped for 6 months or longer at the time of the survey. In the same period, 13.1 million tried to stop but were unsuccessful. Slightly more men stopped smoking than women (1.6 million vs 1.3 million); most were non-Hispanic White adults, most were aged younger than 55 years, most had at least some college education, and most self-identified as straight (Table 1). Among those who stopped smoking for 6 months or longer, the most commonly reported methods used were nicotine products (53.9%, 1.5 million US adults), primarily e-cigarettes used alone or in combination with other methods (40.8%, 1.2 million US adults; Table 2). The least commonly reported methods were non-nicotine, non-prescription drug methods (including a quit line, counseling or clinic, class, or group) (6.3%, 0.2 million US adults). Of the listed methods, the most commonly reported exclusive method selected was e-cigarettes; 26.0% (0.7 million US adults) of adults who stopped smoking from 2021 through 2022 for 6 months or longer selected e-cigarettes as their only listed method.

Discussion

This study identified subpopulations of US adults in NHIS 2022 who stopped or tried to stop smoking and the methods they used. Results showed that smaller proportions of all adults who

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

stopped smoking from 2021 through 2022 were women, Hispanic and non-Hispanic non-White, older (aged ≥55 y), had lower educational attainment (less than some college education), and were non-heterosexual. This may be explained simply by relative subpopulation size (i.e., the US adult population comprises fewer non-heterosexual adults compared to heterosexual adults and more males who smoke than females [8]). Nevertheless, it is important to ensure that specific subpopulations do not get left behind in efforts to curb smoking.

Approximately 40% of adults surveyed in NHIS did not report using any of the surveyed evidence-based methods to stop smoking. Methods containing nicotine, primarily e-cigarettes, were the most commonly-reported methods that were explicitly surveyed. This may provide support for FDA's "nicotine-focused framework for public health" [9], which describes noncombustible nicotine products as "a promising foundation for a comprehensive approach to tobacco harm reduction," FDA's efforts to authorize certain e-cigarette products as "appropriate for the protection of public health" [10], and CDC's statement that "[e]-cigarettes have the potential to benefit adults who smoke . . . if used as a complete substitute for regular cigarettes," [11] while necessarily preventing access to nicotine products by nonsmoking subpopulations, such as adolescents.

This study's strengths include use of a large, nationally representative survey with low bias administered by CDC. NHIS results are thought to be generalizable to the entire US population, because that is the purpose of its sample design by CDC's National Center for Health Statistics [5, 12]. Another strength is the direct measures of stopping smoking (i.e., survey questions answered by adults who actually stopped smoking) as opposed to indirect measures of stopping smoking (e.g., models).

This study also has limitations. First is the inability to parse out individual methods in the "none of the above" category, which is an unavoidable limitation of the NHIS questionnaire design. Because "none of the above" was inferred from respondents who stopped or tried but who did not

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

select any of the surveyed items, the "none of the above" category may be underrepresented in these analyses. Furthermore, the questionnaire did not ask respondents about the duration of treatment use. Future questionnaires should ask respondents for these details. Recall bias may also limit the accuracy of these findings [13].

In conclusion, efforts to reduce smoking among US adults should focus on the subpopulations that stopped smoking the least and encourage use of evidence-based methods.

Acknowledgements

An early version of this research was presented in poster form at the 2024 Society for Research on Nicotine and Tobacco (SRNT) annual meeting (https://doi.org/10.31219/osf.io/2yuw4). The authors thank two anonymous reviewers and participants at the 2024 SRNT meeting for helpful comments and suggestions. This work received no financial support.

The authors declare the following potential conflicts of interests: F.F. provides consulting services through Pinney Associates on tobacco harm reduction on an exclusive basis to Juul Labs Inc, which had no involvement in this article. R.N. has received grant and contractual funding from the National Institutes of Health and the Food and Drug Administration; served as a paid consultant to the Government of Canada via a contract with Industrial Economics Inc; received an honorarium for a virtual meeting from Pfizer Inc; received other NIDA grants paid to his employers; received salary from the Steven Schroeder Institute for Tobacco Research and Policy Studies at The Legacy Foundation, now Truth Initiative, New York University School of Global Public Health; and communicated with Juul Labs personnel, for which there was no compensation, and received hospitality in the form of meals at some meetings; none of which supported the work reported here.

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

References

1. Levy DT, Sánchez-Romero LM, Travis N, Yuan Z, Li Y, Skolnick S, et al. US nicotine vaping product Simsmoke simulation model: the effect of vaping and tobacco control policies on smoking prevalence and smoking-attributable deaths. Int J Environ Res Public Health. 2021;18(9):4876. PubMed https://doi.org/10.3390/ijerph18094876

2. Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–1249. PubMed https://doi.org/10.1016/S0140-6736(20)30752-2

3. Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA. Quit methods used by US adult cigarette smokers, 2014–2016. Prev Chronic Dis. 2017;14:E32. PubMed https://doi.org/10.5888/pcd14.160600

4. Walton K, Wang TW, Prutzman Y, Jamal A, Babb SD. Characteristics and correlates of recent successful cessation among adult cigarette smokers, United States, 2018. Prev Chronic Dis. 2020;17:E154. PubMed http://dx.doi.org/10.5888/pcd17.200173

5. Zablotsky B, Lessem SE, Gindi RM, Maitland AK, Dahlhamer JM, Blumberg SJ. Overview of the 2019 National Health Interview Survey questionnaire redesign. Am J Public Health. 2023;113(4):408–415. PubMed https://doi.org/10.2105/AJPH.2022.307197

6. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco product use among adults — United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(46):1736–1742. PubMed https://doi.org/10.15585/mmwr.mm6946a4

7. Cornelius ME, Loretan CG, Wang TW, Jamal A, Homa DM. Tobacco product use among adults — United States, 2020. MMWR Morb Mortal Wkly Rep. 2022;71(11):397–405. PubMed https://doi.org/10.15585/mmwr.mm7111a1

8. Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, Alcantara IC, et al. Tobacco product use among adults — United States, 2021. MMWR Morb Mortal Wkly Rep. 2023;72(18):475–483. PubMed https://doi.org/10.15585/mmwr.mm7218a1

9. Gottlieb S, Zeller M. A nicotine-focused framework for public health. N Engl J Med. 2017;377(12):1111–1114. PubMed https://doi.org/10.1056/NEJMp1707409

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

10. US Food and Drug Administration. Premarket tobacco product marketing granted orders. Accessed January 26, 2024. https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-granted-orders

11. Centers for Disease Control and Prevention. About electronic cigarettes (e-cigarettes). Accessed January 26, 2024. https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html

12. Centers for Disease Control and Prevention; US Department of Health and Human Services, Division of Health Interview Statistics, National Center for Health Statistics. National Health Interview Survey 2022 survey description. Published 2023. Accessed January 26, 2024. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2022/srvydesc-508.pdf

13. Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res. 2012;14(12):1483–1487. PubMed https://doi.org/10.1093/ntr/nts002

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Table 1. Demographic Characteristics of Adults Who Stopped Smoking (N = 304), or Tried to Stop Smoking but Did Not Stop Smoking from 2021 through 2022 (N = 1,431), National Health Interview Survey 2021–2022[a]

Characteristic	Stopped smoking completely[b], weighted % (95% CI) (weighted N, millions)	Tried to stop smoking but did not stop smoking, weighted % (95% CI) (weighted N, millions)
All adults	100 (2.9)	100 (13.1)
Sex		
Female	45.3 (39.3–51.4) (1.3)	44.2 (41.1–47.2) (5.8)
Male	54.7 (48.6–60.7 (1.6)	55.8 (52.8–58.9) (7.3)
Race or ethnicity		
Hispanic	15.2 (10.8–20.6) (0.4)	12.0 (9.9–14.4) (1.6)
Non-Hispanic Black	11.2 (7.5–15.9) (0.3)	16.1 (13.7–18.6) (2.1)
Non-Hispanic White	67.3 (60.8–73.2) (1.9)	65.1 (62.1–68.0) (8.5)
Non-Hispanic Other	6.3 (3.5–10.3) (0.2)	6.8 (5.4–8.6) (0.9)
Age, y		
18–34	41.9 (35.4–48.7) (1.2)	24.7 (21.9–27.6) (3.2)
35–54	34.2 (27.9–40.9) (1.0)	39.6 (36.4–42.8) (5.2)
55 or older	23.9 (19.0–29.3) (0.7)	35.7 (33.0–38.6) (4.7)
Education		
≤12 years (no diploma)	9.4 (5.8–14.2) (0.3)	18.5 (16.0–21.3) (2.4)
GED certificate or high school diploma	34.4 (28.7–40.5) (1.0)	38.5 (35.5–41.7) (5.0)
Some college (no degree)	18.8 (14.4–23.9) (0.5)	17.1 (15.1–19.3) (2.2)
Associate, undergraduate, or graduate degree	37.3 (31.3–43.8) (1.1)	25.8 (23.2–28.5) (3.4)
Sexual orientation		
Gay/lesbian/bisexual	12.8 (8.6–18.0) (0.4)	5.8 (4.5–7.4) (0.8)
Straight	82.8 (76.7–87.9) (2.4)	90.0 (88.1–91.7) (11.8)
Other	4.4 (1.8–8.8) (0.1)	4.1 (3.0–5.6) (0.5)

[a] Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn and Graubard method.

[b] Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research [4].

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Table 2. Methods Used by Adults Who Stopped Smoking (N = 304), or Tried to Stop Smoking but Did Not Stop Smoking (N = 1,431), National Health Interview Survey, 2021–2022[a]

Method(s)	Stopped smoking completely[b], weighted % (95% CI) (weighted N, millions)	Tried to stop smoking but did not stop smoking, weighted % (95% CI) (weighted N, millions)
Any method	100 (2.9)	100 (13.1)
Nicotine products		
E-cigarettes	40.8 (34.4–47.5) (1.2)	20.7 (18.1–23.4) (2.7)
Exclusively[c]	26.0 (20.6–32.0) (0.7)	11.2 (9.3–13.3) (1.5)
Nicotine gum/lozenge	18.8 (14.1–24.4) (0.5)	19.0 (16.7–21.4) (2.5)
Exclusively[c]	—[d]	4.8 (3.7–6.2) (0.6)
Nicotine patch	15.4 (11.1–20.6) (0.4)	22.1 (19.7–24.6) (2.9)
Exclusively[c]	5.4 (2.8–9.5) (0.2)	7.4 (6.1–9.0) (1.0)
Nicotine nasal spray/inhaler	—[d]	0.9 (0.5–1.7) (0.1)
Exclusively[c]	—[d]	—[d]
One or more of the above	53.9 (47.4–60.3) (1.5)	45.1 (42.0–48.2) (5.9)
Prescription drug products		
Varenicline	5.1 (2.9–8.2) (0.1)	11.3 (9.5–13.3) (1.5)
Exclusively[c]	—[d]	3.0 (2.1–4.2) (0.4)
Bupropion	4.7 (2.6–7.7) (0.1)	7.4 (5.9–9.0) (1.0)
Exclusively[c]	—[d]	1.7 (1.0–2.7) (0.2)
One or more of the above	8.1 (5.3–11.8) (0.2)	16.2 (14.2–18.5) (2.1)
One or more pharmacotherapy (nicotine product incl. e-cigarettes or prescription drug product)	56.6 (49.9–63.1) (1.6)	51.1 (47.9–54.3) (6.7)
Non-nicotine, non-prescription drug methods		
Quit line	3.1 (1.4–5.7) (0.1)	4.3 (3.2–5.7) (0.6)
Exclusively[c]	3.1 (1.4–5.7) (0.1)	—[d]
Counseling	3.1 (1.5–5.7) (0.1)	4.8 (3.6–6.2) (0.6)
Exclusively[c]	—[d]	0.6 (0.3–1.2) (0.1)
Clinic/class/group	—[d]	2.5 (1.7–3.5) (0.3)
Exclusively[c]	—[d]	—[d]
One or more of the above	6.3 (3.9–9.7) (0.2)	7.9 (6.4–9.7) (1.0)
Any of the above[e]	57.5 (50.8–63.9) (1.6)	52.5 (49.2–55.7) (6.9)
None of the above[f]	42.5 (36.1–49.2) (1.2)	47.5 (44.3–50.8) (6.2)

[a] Following Cornelius et al [8], modified Clopper-Pearson confidence limits were calculated by using the Korn and Graubard method.

[b] Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research [4].

[c] Exclusive percentages are expressed among all adults who stopped or tried to stop smoking, not as a percentage of those adults who used the particular method (e.g., 26.0% of all adults who stopped smoking used e-cigarettes exclusively). Exclusive means the respondent selected that particular method but did not select the other methods listed on the questionnaire (e.g., exclusive e-cigarette means reported using e-cigarettes but not nicotine gum or lozenge, nicotine patch, nicotine, nasal spray/inhaler, varenicline, bupropion, a quit line, or counseling).

medRxiv preprint doi: https://doi.org/10.1101/2024.07.11.24310141; this version posted July 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[d] Estimates with an unweighted denominator or numerator less than 10, relative 95% CI width >160%, or degrees of freedom less than 8 are suppressed, consistent with the latest 2023 National Center for Health Statistics standards for rates and counts (https://www.cdc.gov/nchs/data/series/sr_02/sr02-200.pdf).

[e] Stopped smoking "completely" from 2021 through 2022 or tried from 2021 through 2022 and reported using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.

[f] Stopped smoking "completely" from 2021 through 2022 or tried from 2021 through 2022 but did not report using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.